ReviewThe Mount Sinai journal of medicine, New York
Current treatment and recent clinical research in Alzheimer's disease.
Review in The Mount Sinai journal of medicine, New York. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 79 citations in OpenAlex.
- Flavonoids and Alzheimer's disease: reviewing the evidence for neuroprotective potential.Molecular and cellular biochemistry · 2025Review
- Ethnopharmacological Profile, Phytochemistry and Therapeutic Potential ofJournal of nutrition and metabolism · 2025Review
- Protein clearance strategies for disease intervention.Journal of neural transmission (Vienna, Austria : 1996) · 2022Review
- Pharmacokinetic Evaluation of a Novel Donepezil-Loaded Dissolving Microneedle Patch in Rats.Pharmaceutics · 2021Article
- FromFrontiers in pharmacology · 2020Review
- Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.Alzheimer's research & therapy · 2019Article
- Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.Journal of Alzheimer's disease : JAD · 2017Review
- Vanda roxburghii chloroform extract as a potential source of polyphenols with antioxidant and cholinesterase inhibitory activities: identification of a strong phenolic antioxidant.BMC complementary and alternative medicine · 2015Article
- Hippocampal shape is predictive for the development of dementia in a normal, elderly population.Human brain mapping · 2014Article
- Long-term oral administration of hop flower extracts mitigates Alzheimer phenotypes in mice.PloS one · 2014Article
- Selenoprotein-transgenic Chlamydomonas reinhardtii.Nutrients · 2013Article
- Cessation of neoangiogenesis in Alzheimer's disease follows amyloid-beta immunization.Scientific reports · 2013Article
- Management of Dementia and Depression Utilizing In- Home Passive Sensor Data.Gerontechnology : international journal on the fundamental aspects of technology to serve the ageing society · 2013Article
- Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?ACS chemical neuroscience · 2012Review
- Nicotine decreases beta-amyloid through regulating BACE1 transcription in SH-EP1-α4β2 nAChR-APP695 cells.Neurochemical research · 2011Article
- The role of serotonin in respiratory function and dysfunction.Respiratory physiology & neurobiology · 2010Review
- β-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and β-amyloid accumulation.The European journal of neuroscience · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The transition from either epidemiological observation or the bench to rigorously tested clinical trials in patients with Alzheimer's disease is crucial in understanding which treatments are beneficial to patients. The amyloid hypothesis has undergone scrutiny recently, as many trials aimed at reducing amyloid and plaque have been completed or are in the testing phase. Examples include modulation of the secretases involved in beta amyloid formation, anti-aggregation agents, and immunotherapeutic trials. Other therapies targeting hyperphosphorylated tau and novel targets such as enhancement of mitochondrial function, serotonin receptors, receptor for advanced glycation end products, and nerve growth factor, as well as other strategies, are discussed. A brief review of the current Food and Drug Administration-approved treatments is included.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.